Interferon alfa-2b: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Interferon alfa-2b}} | {{Interferon alfa-2b}} | ||
{{CMG}} | {{CMG}} |
Revision as of 20:24, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Interferon alfa-2b is an antiviral drug discovered and marketed by Schering-Plough under the tradename Intron-
®. It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
Category
Antiviral
US Brand Names
INTRON A®
FDA Package Insert
Description | Clinical Pharmacology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages